Publications

Department of Medicine faculty members published more than 3,600 peer-reviewed articles in 2024.

Filter by

Infection control and hospital epidemiology

Implementing strategies to prevent infections in acute-care settings.

2023

Authors: Trivedi KK, Schaffzin JK, Deloney VM, Aureden K, Carrico R, Garcia-Houchins S, Garrett JH, Glowicz J, Lee GM, Maragakis LL, Moody J, Pettis AM, Saint S, Schweizer ML, Yokoe DS, Berenholtz S

JAMA

Cytisinicline for Smoking Cessation: A Randomized Clinical Trial.

2023

Authors: Rigotti NA, Benowitz NL, Prochaska J, Leischow S, Nides M, Blumenstein B, Clarke A, Cain D, Jacobs C

Annals of internal medicine

Risk for Chronic Kidney Disease Progression After Acute Kidney Injury: Findings From the Chronic Renal Insufficiency Cohort Study.

2023

Authors: Muiru AN, Hsu JY, Zhang X, Appel LJ, Chen J, Cohen DL, Drawz PE, Freedman BI, Go AS, He J, Horwitz EJ, Hsu RK, Lash JP, Liu KD, McCoy IE, Porter A, Rao P, Ricardo AC, Rincon-Choles H, Sondheimer J, Taliercio J, Unruh M, Hsu CY, and the CRIC Study Investigators*

European journal of endocrinology

Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.

2023

Authors: Gashaw I, Reif S, Wiesinger H, Kaiser A, Zollmann FS, Scheerans C, Grevel J, Piraino P, Seidel H, Peters M, Rottmann A, Rohde B, Arlt W, Hilpert J

Cortex; a journal devoted to the study of the nervous system and behavior

Increased neural variability in adolescents with ADHD symptomatology: Evidence from a single-trial EEG study.

2023

Authors: Einziger T, Devor T, Ben-Shachar MS, Arazi A, Dinstein I, Klein C, Auerbach JG, Berger A

Open forum infectious diseases

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19.

2023

Authors: Robinson P, Toussi SS, Aggarwal S, Bergman A, Zhu T, Hackman F, Sathish JG, Updyke L, Loudon P, Krishna G, Clevenbergh P, Hernandez-Mora MG, Cisneros Herreros JM, Albertson TE, Dougan M, Thacker A, Baniecki ML, Soares H, Whitlock M, Nucci G, Menon S, Anderson AS, Binks M

Volume 16 of Issue 13 | JACC. Cardiovascular interventions

First-in-Human Multicenter Experience of the Newest Generation Supra-Annular Self-Expanding Evolut FX TAVR System.

2023

Authors: Zaid S, Attizzani GF, Krishnamoorthy P, Yoon SH, Palma Dallan LA, Chetcuti S, Fukuhara S, Grossman PM, Goel SS, Atkins MD, Kleiman NS, Puri R, Bakhtadze B, Byrne T, Ibrahim AW, Grubb KJ, Tully A, Herrmann HC, Faggioni M, Ramlawi B, Khera S, Lerakis S, Dangas GD, Kini AS, Sharma SK, Reardon MJ, Tang GHL

View Abstract

BACKGROUND

The latest-generation Evolut FX TAVR system (Medtronic) offers several potential design improvements over its predecessors, but early reported experience has been limited.

OBJECTIVES

This study sought to report our multicenter, limited market release, first-in-human experience of transcatheter aortic valve replacement (TAVR) with the Evolut FX system and compare it with a single-center PRO+ (Medtronic) experience.

METHODS

From June 27 to September 16, 2022, 226 consecutive patients from 9 US centers underwent transfemoral TAVR with the Evolut FX system for native aortic stenosis (89.4%) or prosthetic valve degeneration (10.6%). Commissural alignment was defined as 0° to 30° between native and FX commissures. Patient, anatomical, and procedural characteristics were retrospectively reviewed, and 30-day clinical and echocardiographic outcomes per Valve Academic Research Consortium-3 definitions were reported.

RESULTS

Of 226 patients, 34.1% were low risk, 4% had a bicuspid valve, and 11.5% had a horizontal root (≥60°). Direct Inline sheath (Medtronic) was used in 67.6% and Lunderquist stiff wire (Cook Medical) in 35.4% of cases. Optimal hat marker orientation during deployment was achieved in 98.4%, with commissural alignment in 96.5%. At 30 days, 14.3% mild, 0.9% moderate, and no severe paravalvular leak were observed. Compared with the Evolut PRO+ experience from 1 center, FX had a more symmetrical implantation with shallower depth at the left coronary cusp (P < 0.001), fewer device recaptures (26.1% vs 39.5%; P = 0.004), and improved commissural alignment (96.5% vs 80.2%; P < 0.001).

CONCLUSIONS

The Evolut FX system demonstrated favorable 30-day outcomes with a significant improvement over PRO+ in achieving commissural alignment, fewer device recaptures, and more symmetrical implantation. These features may benefit younger patients undergoing TAVR with the supra-annular, self-expanding valve, where lifetime management would be important.

View on PubMed

NAM Perspectives